Denovo Biolabs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.83 M
as on 17-07-2024
- Revenue -37.57%
(FY 2023)
- Profit -35.33%
(FY 2023)
- Ebitda -74.73%
(FY 2023)
- Net Worth 7.02%
(FY 2023)
- Total Assets -14.02%
(FY 2023)
About Denovo Biolabs
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.83 M.
Devaramani Manjunath, Babulal Saini, and Dinesh Saini serve as directors at the Company.
- CIN/LLPIN
U85191MH2013PTC243475
- Company No.
243475
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Borivali East, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Denovo Biolabs Private Limited offer?
Denovo Biolabs Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Chemical Test Kits, Rapid Test Kit, Elisa Kits, Medical Consultants & Clinics, Medical Consultancy Services, pH Buffer Solution, Laboratory Reagents, Anti Cancer Medicines, Monoclonal Antibodies.
Who are the key members and board of directors at Denovo Biolabs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devaramani Manjunath  | Director | 10-Jun-2013 | Current |
| Babulal Saini | Director | 21-May-2013 | Current |
| Dinesh Saini | Director | 21-May-2013 | Current |
Financial Performance of Denovo Biolabs.
Denovo Biolabs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 37.57% decrease. The company also saw a substantial fall in profitability, with a 35.33% decrease in profit. The company's net worth moved up by a moderate rise of 7.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Denovo Biolabs?
In 2023, Denovo Biolabs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 22 May 2023 | ₹4.03 M | Open |
Sidbi Creation Date: 25 Oct 2019 | ₹4.80 M | Open |
How Many Employees Work at Denovo Biolabs?
Unlock and access historical data on people associated with Denovo Biolabs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Denovo Biolabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Denovo Biolabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED.webp){kind=small}
